为您找到"
ANX-09
"相关结果约100,000,000个
Safety, Tolerability, and Clinical Pharmacology of ANX009, an Inhibitory Antibody Fab Fragment Against C1q, Administered Subcutaneously to Healthy Volunteers Anita Grover1, Jeffrey Teigler1, Emily Radomile1, Henk-André Kroon1, Ted Yednock1, Sanjay Keswani1, Shawn Rose1
ANX-009: a C1q inhibitors Drug, Initially developed by Annexon, Inc., Now, its global highest R&D status is Phase 1, Mechanism: C1q inhibitors (Complement C1q subcomponent inhibitors), Therapeutic Areas: Immune System Diseases,Skin and Musculoskeletal Diseases,Urogenital Diseases, Active Indication: Lupus Nephritis, Active Org.: Annexon, Inc..
ANX 009 is a C1q inhibitor and a subcutaneous formulation of an antigen-binding fragment (Fab), being developed by Annexon for the treatment of
The main purpose of this study is to determine the safety and tolerability of repeat doses of ANX009 in participants with lupus nephritis (LN).
News for ANX009 / Annexon BiosciResults of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis (ACR Convergence 2023) - "In this interim analysis, ANX009 administered subcutaneously was well tolerated and demonstrated C1q target engagement and complement ...
The main purpose of this study is to determine the safety and tolerability of repeat doses of ANX009 in participants with lupus nephritis (LN).
At a glance Drugs ANX-009 (Primary) Indications Lupus nephritis Focus Adverse reactions Sponsors Annexon Most Recent Events 26 Aug 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health. 22 Aug 2024 Status changed from recruiting to completed. 15 Nov 2023 Interim results assessing safety and tolerability of ANX009 ,presented at the ACR Convergence 2023. 26 Aug 2024 Last ...
113 Followers, 185 Following, 1 Posts - See Instagram photos and videos from Annu (@_anx09._)
Safety, Tolerability, and Clinical Pharmacology of ANX009, an Inhibitory Antibody Fab Fragment Against C1q, Administered Subcutaneously to Healthy Volunteers
The C1q inhibitor ANX009 was found to be safe, tolerable, and have favorable pharmacology in a phase 1 clinical trial with healthy individuals, supporting its advancement into testing its efficacy in patients with complement-mediated autoimmune disorders such as cold agglutinin disease (CAD). These ...